Murat O. Arcasoy, MD

Duke University School of Medicine
DUMC Box 3912
Durham, NC
USA 27710
577 Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
3032 Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia:  Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial